{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:19:27Z","timestamp":1770355167357,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13104-016-2243-8","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T12:27:52Z","timestamp":1473251272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-9284","authenticated-orcid":false,"given":"Paul","family":"Wicks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Rasouliyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Katic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beenish","family":"Nafees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emuella","family":"Flood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Sasan\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"2243_CR1","first-page":"S15","volume":"19","author":"MJ Tullman","year":"2013","unstructured":"Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19:S15\u201320.","journal-title":"Am J Manag Care"},{"key":"2243_CR2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3111\/13696998.2014.940422","volume":"17","author":"N Bergvall","year":"2014","unstructured":"Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ. 2014;17:696\u2013707.","journal-title":"J Med Econ"},{"key":"2243_CR3","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.18553\/jmcp.2013.19.s1.S24","volume":"19","author":"J Menzin","year":"2013","unstructured":"Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19:S24\u201340.","journal-title":"J Manag Care Pharm"},{"key":"2243_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","volume":"18","author":"V Devonshire","year":"2011","unstructured":"Devonshire V, Lapierre Y, Macdonnel R, Ramo-Tello C, Patti F, Fontoura P, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69\u201377.","journal-title":"Eur J Neurol"},{"key":"2243_CR5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-2377-13-138","volume":"13","author":"N Agashivala","year":"2013","unstructured":"Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective study. BMC Neurol. 2013;13:138.","journal-title":"BMC Neurol"},{"issue":"1","key":"2243_CR6","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.2196\/jmir.1687","volume":"13","author":"P Wicks","year":"2011","unstructured":"Wicks P, Massagli M, Kulkarni A, Dastani H. Online development of a tool to measure barriers to adherence: the multiple sclerosis treatment adherence questionnaire (MS-TAQ). J Med Internet Res. 2011;13(1):e12.","journal-title":"J Med Internet Res"},{"key":"2243_CR7","unstructured":"Gilenya [package insert]. Stein (CH): Novartis Pharma Stein AG; 2012."},{"issue":"5","key":"2243_CR8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. TRANSFORMS study group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315.","journal-title":"N Engl J Med"},{"key":"2243_CR9","unstructured":"Tecfidera. Cambridge (MA): Biogen Inc; 2013."},{"issue":"2","key":"2243_CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/acn3.148","volume":"2","author":"V Viglietta","year":"2015","unstructured":"Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2(2):103\u201318.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"2243_CR11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.msard.2014.03.003","volume":"3","author":"JT Phillips","year":"2014","unstructured":"Phillips JT, Hutchinson M, Fox R, Gold R, Havrdova E. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014;3(4):513\u20139.","journal-title":"Mult Scler Relat Disord"},{"issue":"1\u20132","key":"2243_CR12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2012.09.009","volume":"323","author":"D Ontaneda","year":"2012","unstructured":"Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;323(1\u20132):167\u201372.","journal-title":"J Neurol Sci"},{"issue":"2","key":"2243_CR13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"26","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;26(2):12.","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"2243_CR14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-10-70","volume":"18","author":"P Wicks","year":"2012","unstructured":"Wicks P, Vaughan TE, Massagli MP. The multiple sclerosis rating scale, revised (MSRS-R): development, refinement, and psychometric validation using an online community. Health Qual Life Outcomes. 2012;18(10):70.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"2243_CR15","doi-asserted-by":"crossref","first-page":"e59707","DOI":"10.1371\/journal.pone.0059707","volume":"8","author":"R Bove","year":"2013","unstructured":"Bove R, Secor E, Healy BC, Musallam A, Vaughan T, Glanz BI, et al. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease progression. PLoS ONE. 2013;8(3):e59707.","journal-title":"PLoS ONE"},{"issue":"2","key":"2243_CR16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.45.2.251","volume":"45","author":"MJ Hohol","year":"1995","unstructured":"Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45(2):251\u20135.","journal-title":"Neurology"},{"issue":"2","key":"2243_CR17","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.2196\/jmir.1549","volume":"12","author":"P Wicks","year":"2010","unstructured":"Wicks P, Massagli M, Frost J, Brownstein C, Okun S, Vaughan T, et al. Sharing health data for better outcomes on PatientsLikeMe. J Med Internet Res. 2010;12(2):e19.","journal-title":"J Med Internet Res"},{"issue":"16","key":"2243_CR18","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M. A Solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409\u201319.","journal-title":"Stat Med"},{"issue":"12","key":"2243_CR19","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/QAD.0b013e3281532b31","volume":"21","author":"RS Braithwaite","year":"2007","unstructured":"Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21(12):1579\u201389.","journal-title":"AIDS"},{"key":"2243_CR20","first-page":"129","volume":"2","author":"M Brod","year":"2008","unstructured":"Brod M, Rousculp M, Cameron A. Understanding compliance issues for daily self-injectable treatment in ambulatory care settings. Patient Prefer Adherence. 2008;2:129\u201336.","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl 4","key":"2243_CR21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","volume":"9","author":"P Conte","year":"2004","unstructured":"Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9(Suppl 4):28\u201337.","journal-title":"Oncologist"},{"issue":"1","key":"2243_CR22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","volume":"28","author":"H Tan","year":"2011","unstructured":"Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51\u201361.","journal-title":"Adv Ther"},{"issue":"2","key":"2243_CR23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","volume":"30","author":"SC Steinberg","year":"2010","unstructured":"Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89\u2013100.","journal-title":"Clin Drug Investig"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-016-2243-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T21:40:39Z","timestamp":1657230039000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-016-2243-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2243"],"URL":"https:\/\/doi.org\/10.1186\/s13104-016-2243-8","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]},"article-number":"434"}}